12月23日,医药公司诺和诺德(NVO)股价在盘前大涨5.44%,引发市场广泛关注。
分析人士指出,这一涨幅可能是因为市场对诺和诺德公司新一代抗肥胖症药物"塞洛那龙"抱有期待。该药物目前正在美国FDA的审批程序中,预计明年将获批上市。相关数据显示,该新药具有较高的减重效果,在临床试验中参与者平均体重减轻近20%。
就在前一日,诺和诺德遭遇大跌超20%,因为公司当天公布的另一款减肥药数据未达预期,引发了市场担忧。而业内人士认为,只要"塞洛那龙"获批成功,诺和诺德在减肥药市场前景依然十分乐观,因此投资者纷纷买入公司股票。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.